BACKGROUND: Monocyte activation may contribute to neuronal injury in aviremic HIV-infected adults; data are lacking in children. We examined the relation between monocyte activation markers and early and long-term neurodevelopmental outcomes in early-treated HIV-infected children. SETTING: Prospective study of infant and child neurodevelopmental outcomes nested within a randomized clinical trial (NCT00428116) and extended cohort study in Kenya. METHODS:HIV-infected infants (N = 67) initiated antiretroviral therapy (ART) at age <5 months. Plasma soluble (s) CD163 (sCD163), sCD14, and neopterin were measured before ART (entry) and 6 months later. Milestone attainment was ascertained monthly during 24 months, and neuropsychological tests were performed at 5.8-8.2 years after initiation of ART (N = 27). The relationship between neurodevelopment and sCD163, sCD14, and neopterin at entry and 6 months after ART was assessed using Cox proportional hazards models and linear regression. RESULTS:Infants with high entry sCD163 had unexpected earlier attainment of supported sitting (5 vs 6 months; P = 0.006) and supported walking (10 vs 12 months; P = 0.02) with trends in adjusted analysis. Infants with high 6-month post-ART sCD163 attained speech later (17 vs 15 months; P = 0.006; adjusted hazard ratio, 0.47; P = 0.02), threw toys later (18 vs 17 months; P = 0.01; adjusted hazard ratio, 0.53; P = 0.04), and at median 6.8 years after ART, had worse neuropsychological test scores (adj. mean Z-score differences, cognition, -0.42; P = 0.07; short-term memory, -0.52; P = 0.08; nonverbal test performance, -0.39, P = 0.05). CONCLUSIONS: Before ART, monocyte activation may reflect transient neuroprotective mechanisms in infants. After ART and viral suppression, monocyte activation may predict worse short- and long-term neurodevelopment outcomes.
RCT Entities:
BACKGROUND: Monocyte activation may contribute to neuronal injury in aviremic HIV-infected adults; data are lacking in children. We examined the relation between monocyte activation markers and early and long-term neurodevelopmental outcomes in early-treated HIV-infectedchildren. SETTING: Prospective study of infant and child neurodevelopmental outcomes nested within a randomized clinical trial (NCT00428116) and extended cohort study in Kenya. METHODS:HIV-infectedinfants (N = 67) initiated antiretroviral therapy (ART) at age <5 months. Plasma soluble (s) CD163 (sCD163), sCD14, and neopterin were measured before ART (entry) and 6 months later. Milestone attainment was ascertained monthly during 24 months, and neuropsychological tests were performed at 5.8-8.2 years after initiation of ART (N = 27). The relationship between neurodevelopment and sCD163, sCD14, and neopterin at entry and 6 months after ART was assessed using Cox proportional hazards models and linear regression. RESULTS:Infants with high entry sCD163 had unexpected earlier attainment of supported sitting (5 vs 6 months; P = 0.006) and supported walking (10 vs 12 months; P = 0.02) with trends in adjusted analysis. Infants with high 6-month post-ARTsCD163 attained speech later (17 vs 15 months; P = 0.006; adjusted hazard ratio, 0.47; P = 0.02), threw toys later (18 vs 17 months; P = 0.01; adjusted hazard ratio, 0.53; P = 0.04), and at median 6.8 years after ART, had worse neuropsychological test scores (adj. mean Z-score differences, cognition, -0.42; P = 0.07; short-term memory, -0.52; P = 0.08; nonverbal test performance, -0.39, P = 0.05). CONCLUSIONS: Before ART, monocyte activation may reflect transient neuroprotective mechanisms in infants. After ART and viral suppression, monocyte activation may predict worse short- and long-term neurodevelopment outcomes.
Authors: Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Dana Totin; Christopher Ndugwa; Francis Mmiro; Robert T Perry; J Brooks Jackson; Richard D Semba Journal: J Nutr Date: 2002-03 Impact factor: 4.798
Authors: L A Ryan; J Zheng; M Brester; D Bohac; F Hahn; J Anderson; W Ratanasuwan; H E Gendelman; S Swindells Journal: J Infect Dis Date: 2001-08-15 Impact factor: 5.226
Authors: T Fischer-Smith; S Croul; A E Sverstiuk; C Capini; D L'Heureux; E G Régulier; M W Richardson; S Amini; S Morgello; K Khalili; J Rappaport Journal: J Neurovirol Date: 2001-12 Impact factor: 2.643
Authors: Tinyiko G Makhubele; Helen C Steel; Ronald Anderson; Gisela van Dyk; Annette J Theron; Theresa M Rossouw Journal: Mediators Inflamm Date: 2016-02-25 Impact factor: 4.711
Authors: Adriana Weinberg; Mark J Giganti; Patricia A Sirois; Grace Montepiedra; Jennifer Canniff; Allison Agwu; Michael J Boivin; Suad Kapetanovic; Mark J Abzug Journal: AIDS Date: 2022-04-19 Impact factor: 4.632
Authors: Suad Kapetanovic; Mark J Giganti; Mark J Abzug; Jane C Lindsey; Patricia A Sirois; Grace Montepiedra; Jennifer Canniff; Allison Agwu; Michael J Boivin; Adriana Weinberg Journal: AIDS Date: 2021-07-15 Impact factor: 4.632
Authors: Monray E Williams; Anicia Janse Van Rensburg; Du Toit Loots; Petrus J W Naudé; Shayne Mason Journal: Viruses Date: 2021-12-18 Impact factor: 5.048
Authors: Lee Fairlie; Miriam Chernoff; Mark F Cotton; Mutsa Bwakura-Dangarembizi; Avy Violari; Itziar Familiar-Lopez; Linda Barlow-Mosha; Portia Kamthunzi; Katie McCarthy; Patrick Jean-Philippe; Barbara Laughton; Paul E Palumbo; Michael J Boivin Journal: Front Pediatr Date: 2022-08-03 Impact factor: 3.569